Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

A neuroscientist reviewing brain scan imagery for an article about Huntington's disease gene therapy

U.K. scientists slow Huntington’s disease progression for the first time

By / / Good News For Humankind

Huntington’s disease gene therapy has achieved what researchers once considered impossible, with a single surgical injection slowing overall disease progression by 75% and functional decline by 60% in a University College London clinical trial. The experimental treatment, AMT-130, permanently reprograms neurons to stop producing the toxic protein responsible for destroying brain cells in this fatal inherited disorder. For the roughly 41,000 Americans living with Huntington’s and 200,000 more at genetic risk, the word “stable” now carries real clinical meaning. Beyond one disease, the gene-silencing techniques validated here are accelerating research into Alzheimer’s, Parkinson’s, and other neurological conditions affecting tens of millions worldwide.

Aerial view of a coastal industrial facility at dusk for an article about osmotic power plant technology in Fukuoka Japan

Japan switches on its first osmotic power plant in Fukuoka

By / / Good News For Humankind

Osmotic power has moved from laboratory concept to working reality with the opening of Japan’s first salinity gradient energy facility in Fukuoka. The plant harnesses the natural pressure difference between fresh water and concentrated brine waste from an adjacent desalination plant, generating clean electricity around the clock without fuel or weather dependence. Estimated to produce enough power for roughly 220 households annually, it is only the second facility of its kind in the world built for continuous operation. Its significance lies in the blueprint it offers: osmotic plants can attach to existing desalination infrastructure worldwide, turning a disposal problem into a steady power source.

A neuroscientist reviewing brain activity data on a monitor for an article about epilepsy drug RAP-219

New epilepsy drug cuts seizures by nearly 80% in mid-stage trial

By / / Good News For Humankind

Epilepsy drug RAP-219 has shown striking results in a mid-stage clinical trial, reducing seizures by a median of 77.8% in adults whose epilepsy had not responded to existing medications. Developed by Rapport Therapeutics, the drug works by precisely targeting overactive brain regions rather than broadly suppressing electrical activity across the whole brain. Nearly one in four participants became completely seizure-free during the eight-week study. The trial’s use of implanted neurostimulation devices provided objective, real-time brain data that strengthens confidence in the findings. Phase 3 trials are expected to begin in 2026.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

FDA approves twice-yearly lenacapavir HIV prevention shot with 99.9% effectiveness

By / / Good News For Humankind

Lenacapavir HIV prevention has reached a landmark moment: the FDA has approved the twice-yearly injectable drug — brand name Yeztugo — as the first long-acting PrEP option in history. Clinical trials showed it stopped transmission in more than 99.9% of participants, outperforming daily oral PrEP across tens of thousands of people. The breakthrough matters because adherence to daily medication has always been the weak point in HIV prevention, particularly in high-burden communities facing stigma and limited clinic access. Gilead has also signed royalty-free licensing agreements to supply affordable versions to 120 countries, prioritizing sub-Saharan Africa, Southeast Asia, and the Caribbean.

A healthcare worker caring for a newborn in a clinical setting for an article about newborn malaria treatment

World’s first malaria treatment approved for newborn babies

By / / Good News For Humankind

Newborn malaria treatment reached a historic milestone as regulators approved Coartem Baby, the first antimalarial drug designed specifically for infants weighing under 5 kilograms. Developed through a partnership between Novartis and the non-profit Medicines for Malaria Venture, the dissolvable, cherry-flavored medication fills a gap that persisted for decades, leaving the most fragile newborns without a safe, approved option. Approval has been fast-tracked across eight African countries where need is greatest, with Novartis committing to largely not-for-profit pricing. For the youngest infants born into high-transmission environments, this changes everything.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record, for article on nuclear fusion ignition

U.K. commits £21.7 billion to carbon capture and storage across two industrial clusters

By / / Good News For Humankind

Carbon capture and storage gets a major boost as the UK commits up to £21.7 billion over 25 years to build CCS infrastructure across two historic industrial regions. The investment targets HyNet in the North West and the East Coast Cluster near Teesside, expected to create 4,000 direct jobs and support up to 50,000 long-term. Initial projects will remove more than 8.5 million tonnes of CO₂ annually while helping hard-to-decarbonize industries like steel, cement, and chemicals stay competitive. The UK’s North Sea geology offers an estimated 200 years of storage capacity, giving this commitment rare real-world credibility.

A researcher examining a vial in a cancer immunotherapy laboratory for an article about personalized mRNA cancer vaccine

Personalized mRNA vaccine keeps pancreatic cancer at bay six years after treatment

By / / Good news links

Personalized mRNA cancer vaccine shows remarkable results in a small but significant trial for pancreatic cancer, one of medicine’s most stubborn killers. Six years after treatment, seven of eight patients who mounted an immune response remain alive — extraordinary for a disease with a five-year survival rate below 13%. The custom-built vaccine targets genetic mutations unique to each patient’s tumor, training the immune system to eliminate remaining cancer cells after surgery. New findings suggest the immune response may be self-sustaining, with helper T cells replenishing the killer T cells that attack cancer. A larger Phase 2 trial is now underway.

A surgical team performing a complex organ procedure for an article about bladder transplant surgery, for article on bladder transplant

California surgeons perform the world’s first successful bladder transplant

By / / Good News For Humankind

Bladder transplant surgery has been successfully performed on a human patient for the first time in medical history. Oscar Larrainzar, a 41-year-old California father of four, received a donor bladder and kidney simultaneously in early May 2025, after cancer treatment left him without either organ. He has since been taken off dialysis entirely. The procedure was developed over four years by surgeons at USC and UCLA, who now plan a formal clinical trial to refine the technique. For patients who have lost bladder function, transplantation is no longer theoretical.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

Annual jab for HIV protection passes trial hurdle

By / / Good News For Humankind

A once-yearly HIV prevention shot has just cleared its first safety trial, with the drug lenacapavir still detectable in participants’ bodies a full 56 weeks after a single injection. That’s a hopeful sign for people who find daily prevention pills hard to maintain — whether because of stigma, unstable housing, or simply the grind of remembering. Earlier trials of twice-yearly lenacapavir already showed striking results, and researchers are now testing whether one shot a year could work just as well. With nearly 40 million people living with HIV globally, a prevention tool this simple could reshape what protection looks like — especially for communities where daily medication has never been realistic.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record, for article on nuclear fusion ignition

France runs fusion reactor for record 22 minutes

By / / Good News For Humankind

A fusion reactor in southern France has kept a hydrogen plasma stable for 1,337 seconds — more than 22 minutes — beating the previous record by roughly 25%. The WEST Tokamak pulled this off using just 2 megawatts of heating power, and crucially, without damaging the reactor’s interior, which is the part that has tripped up so many earlier attempts. The data feeds directly into ITER, the much larger international fusion project being built nearby. Net energy gain — the real threshold for practical fusion — still hasn’t been reliably crossed, and this milestone doesn’t change that. But each stable second brings the dream of clean, limitless energy closer to something the world can actually build.